MA40031A - Nucléosides substitués, nucléotides et analogues de ceux-ci - Google Patents

Nucléosides substitués, nucléotides et analogues de ceux-ci

Info

Publication number
MA40031A
MA40031A MA040031A MA40031A MA40031A MA 40031 A MA40031 A MA 40031A MA 040031 A MA040031 A MA 040031A MA 40031 A MA40031 A MA 40031A MA 40031 A MA40031 A MA 40031A
Authority
MA
Morocco
Prior art keywords
analogs
nucleotides
substituted nucleosides
nucleosides
nucleotide analogs
Prior art date
Application number
MA040031A
Other languages
English (en)
French (fr)
Inventor
Leonid Beigelman
Lawrence M Blatt
Natalia Dyatkina
David Bernard Smith
Julian Alexander Symons
Original Assignee
Alios Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alios Biopharma Inc filed Critical Alios Biopharma Inc
Publication of MA40031A publication Critical patent/MA40031A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA040031A 2014-06-24 2015-06-22 Nucléosides substitués, nucléotides et analogues de ceux-ci MA40031A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462016219P 2014-06-24 2014-06-24
US201462034629P 2014-08-07 2014-08-07
US201462061819P 2014-10-09 2014-10-09

Publications (1)

Publication Number Publication Date
MA40031A true MA40031A (fr) 2015-12-30

Family

ID=54868667

Family Applications (1)

Application Number Title Priority Date Filing Date
MA040031A MA40031A (fr) 2014-06-24 2015-06-22 Nucléosides substitués, nucléotides et analogues de ceux-ci

Country Status (17)

Country Link
US (4) US9603863B2 (enExample)
EP (1) EP3160475B1 (enExample)
JP (1) JP6669675B2 (enExample)
CN (1) CN106604734B (enExample)
AP (1) AP2016009653A0 (enExample)
AU (1) AU2015280234B2 (enExample)
CA (1) CA2952959C (enExample)
EA (1) EA201692537A1 (enExample)
IL (1) IL249627A0 (enExample)
MA (1) MA40031A (enExample)
MX (1) MX2016017381A (enExample)
NZ (1) NZ727582A (enExample)
PH (1) PH12016502563A1 (enExample)
SG (1) SG11201610597QA (enExample)
TN (1) TN2016000566A1 (enExample)
TW (1) TW201613613A (enExample)
WO (1) WO2015200205A1 (enExample)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12013500035A1 (en) 2010-07-22 2013-03-11 Gilead Sciences Inc Methods and compounds for treating paramyxoviridae virus infections
SG10201610936RA (en) 2011-12-22 2017-02-27 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
US8980865B2 (en) 2011-12-22 2015-03-17 Alios Biopharma, Inc. Substituted nucleotide analogs
US8916538B2 (en) 2012-03-21 2014-12-23 Vertex Pharmaceuticals Incorporated Solid forms of a thiophosphoramidate nucleotide prodrug
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
CN110684067A (zh) 2012-12-21 2020-01-14 艾丽奥斯生物制药有限公司 取代的核苷和核苷酸
WO2014100498A1 (en) 2012-12-21 2014-06-26 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
WO2014165704A1 (en) 2013-04-05 2014-10-09 Vertex Pharmaceuticals, Inc. Hepatitis c viral infection treatment using a combination of compounds
US9815864B2 (en) 2013-06-26 2017-11-14 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
EP3424938B1 (en) 2013-06-26 2020-07-22 Janssen BioPharma, Inc. 4'-azidoalkyl-substituted nucleosides, nucleotides and analogs thereof
AU2014331863C1 (en) 2013-10-11 2019-05-16 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
CN117379452A (zh) 2014-06-24 2024-01-12 艾丽奥斯生物制药有限公司 取代的核苷、核苷酸和其类似物
AU2015280234B2 (en) 2014-06-24 2021-04-01 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
MX381291B (es) 2014-09-26 2025-03-12 Riboscience Llc Derivados de nucleósidos sustituidos con 4'-vinilo como inhibidores de la replicación del arn del virus respiratorio sincitial.
EP3204020B1 (en) * 2014-10-06 2023-01-18 ImmunityBio, Inc. Treating viral hemorrhagic fever with nk-92 cells
US9908914B2 (en) 2014-10-28 2018-03-06 Alios Biopharma, Inc. Methods of preparing substituted nucleoside analogs
MA41213A (fr) 2014-12-19 2017-10-24 Alios Biopharma Inc Nucléosides substitués, nucléotides et analogues de ceux-ci
MA41441A (fr) 2014-12-19 2017-12-12 Alios Biopharma Inc Nucléosides substitués, nucléotides et analogues de ceux-ci
SG10202105371YA (en) 2014-12-26 2021-07-29 Univ Emory N4-hydroxycytidine and derivatives and anti-viral uses related thereto
GEAP202215528A (en) 2015-03-06 2022-11-10 Atea Pharmaceuticals Inc B-D-2'-DEOXY-2'a-FLUORO-2'-B-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT
MX383931B (es) 2015-03-11 2025-03-14 Janssen Biopharma Inc Compuestos de aza-piridona y usos de estos.
EA201892448A1 (ru) * 2016-04-28 2019-06-28 Эмори Юниверсити Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения
US10202412B2 (en) 2016-07-08 2019-02-12 Atea Pharmaceuticals, Inc. β-D-2′-deoxy-2′-substituted-4′-substituted-2-substituted-N6-substituted-6-aminopurinenucleotides for the treatment of paramyxovirus and orthomyxovirus infections
BR112019004297A2 (pt) 2016-09-07 2019-05-28 Atea Pharmaceuticals Inc método, uso de uma quantidade eficaz de um composto, composto, e, composição farmacêutica.
SG11201906163TA (en) 2017-02-01 2019-08-27 Atea Pharmaceuticals Inc Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus
ES2938859T3 (es) 2017-05-01 2023-04-17 Gilead Sciences Inc Una forma cristalina de (S)-2-etilbutilo 2-(((S)-(((2R,3S,4R,5R)-5-(4-aminopirrolo[2,1-f][1,2,4]triazin-7-il)-5-ciano-3,4-dihidroxitetrahidrofuran-2-il)metoxi)(fenoxi)fosforil)amino)propanoato
WO2019014247A1 (en) 2017-07-11 2019-01-17 Gilead Sciences, Inc. COMPOSITIONS COMPRISING POLYMERASE RNA INHIBITOR AND CYCLODEXTRIN FOR THE TREATMENT OF VIRAL INFECTIONS
US11149049B2 (en) 2017-09-18 2021-10-19 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
FI3706762T3 (fi) 2017-12-07 2024-12-13 Univ Emory N4-hydroksisytidiini ja johdannaisia sekä niihin liittyviä virusten vastaisia käyttötapoja
US20210308168A1 (en) * 2018-03-07 2021-10-07 Emory University 4'-halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto
EP3773753A4 (en) 2018-04-10 2021-12-22 ATEA Pharmaceuticals, Inc. TREATMENT OF PATIENTS INFECTED WITH THE HEPATITIS C VIRUS WITH CIRRHOSIS
EA202192433A1 (ru) 2019-03-06 2021-12-28 Глэксосмитклайн Интеллекчуал Проперти (№2) Лимитед Соединения, полезные в терапии вич
CN114072407A (zh) * 2019-04-02 2022-02-18 阿里戈斯治疗公司 靶向prmt5的化合物
CN118662520A (zh) 2020-01-27 2024-09-20 吉利德科学公司 用于治疗SARS CoV-2感染的方法
TWI874791B (zh) 2020-02-18 2025-03-01 美商基利科學股份有限公司 抗病毒化合物
EP4106876B1 (en) * 2020-02-18 2025-09-17 Gilead Sciences, Inc. Antiviral compounds
TWI794742B (zh) 2020-02-18 2023-03-01 美商基利科學股份有限公司 抗病毒化合物
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
US11613553B2 (en) 2020-03-12 2023-03-28 Gilead Sciences, Inc. Methods of preparing 1′-cyano nucleosides
AR121620A1 (es) 2020-03-20 2022-06-22 Gilead Sciences Inc Profármacos de nucleósidos 4’-c-sustituidos-2-halo-2’-deoxiadenosina y métodos de preparación y uso de los mismos
EP4132651B1 (en) 2020-04-06 2026-03-18 Gilead Sciences, Inc. Inhalation formulations of 1'-cyano substituted carbanucleoside analogs
US20230310481A1 (en) * 2020-04-14 2023-10-05 Janssen Pharmaceuticals, Inc. Bi- and monocyclic nucleoside analogs for treatment of hepatitis e
ES3041698T3 (en) 2020-05-29 2025-11-13 Gilead Sciences Inc Remdesivir for the treatment of viral infections
EP4172160A2 (en) 2020-06-24 2023-05-03 Gilead Sciences, Inc. 1'-cyano nucleoside analogs and uses thereof
EP4200301B1 (en) 2020-08-24 2025-02-26 Gilead Sciences, Inc. Phospholipid compounds and uses thereof
HUE067491T2 (hu) 2020-08-27 2024-10-28 Gilead Sciences Inc Vegyületek és eljárások vírusfertõzések kezelésére
TWI811812B (zh) 2020-10-16 2023-08-11 美商基利科學股份有限公司 磷脂化合物及其用途
KR102923359B1 (ko) 2021-04-16 2026-02-05 길리애드 사이언시즈, 인코포레이티드 아미드를 사용한 카르바뉴클레오시드를 제조하는 방법
JP2024525164A (ja) 2021-06-17 2024-07-10 アテア ファーマシューティカルズ， インコーポレイテッド 有利な抗ｈｃｖ併用療法
CN113735929A (zh) * 2021-07-21 2021-12-03 海化生命(厦门)科技有限公司 一种抗冠状病毒的化合物及其制备方法与应用
EP4387977A1 (en) 2021-08-18 2024-06-26 Gilead Sciences, Inc. Phospholipid compounds and methods of making and using the same
US11541071B1 (en) 2021-12-16 2023-01-03 Ascletis BioScience Co., Ltd Nucleoside derivatives and methods of use thereof
CN116554249B (zh) * 2022-01-28 2025-03-18 北京恩泰伟医药科技有限公司 抗病毒化合物及其用途
AU2023227794A1 (en) 2022-03-02 2024-10-17 Gilead Sciences, Inc. Compounds and methods for treatment of viral infections
JP2025509635A (ja) 2022-03-15 2025-04-11 ローム・セラピューティクス・インコーポレイテッド 疾患を治療するための化合物及び方法
CN116947947A (zh) * 2022-04-20 2023-10-27 中国科学院上海药物研究所 抗病毒核苷类似物及其药物组合物和用途
CN116535385B (zh) * 2022-08-29 2025-03-11 苏州华一新能源科技股份有限公司 一种制备硫酸乙烯酯的方法
US12357577B1 (en) 2024-02-02 2025-07-15 Gilead Sciences, Inc. Pharmaceutical formulations and uses thereof
CN116589510B (zh) * 2023-04-20 2025-08-26 安徽大学 一种氟代苄基核糖中间体的制备方法与应用

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5432272A (en) 1990-10-09 1995-07-11 Benner; Steven A. Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
DZ3487A1 (fr) 2001-01-22 2002-07-25 Merck Sharp & Dohme Derives de nucleoside comme inhibiteurs de l'arn polymerase virale d'arn-dependant
WO2002069903A2 (en) * 2001-03-06 2002-09-12 Biocryst Pharmaceuticals, Inc. Nucleosides, preparation thereof and use as inhibitors of rna viral polymerases
US20040138170A1 (en) 2002-03-06 2004-07-15 Montgomery John A. Nucleosides, preparation thereof and use as inhibitors of rna viral polymerases
ES2342069T4 (es) 2003-09-05 2011-01-26 Anadys Pharmaceuticals, Inc. Ligandos de tlr7 para el tratamiento de la hepatitis c.
JP2008508319A (ja) * 2004-07-29 2008-03-21 メタバシス・セラピューティクス・インコーポレイテッド 新規ヌクレオシド誘導体
US20090318380A1 (en) 2007-11-20 2009-12-24 Pharmasset, Inc. 2',4'-substituted nucleosides as antiviral agents
US20090176732A1 (en) 2007-12-21 2009-07-09 Alios Biopharma Inc. Protected nucleotide analogs
US8475804B2 (en) 2009-02-20 2013-07-02 U.S. Army Medical Research And Material Command Compositions and methods for treatment of filovirus-mediated diseases
WO2010108135A1 (en) 2009-03-20 2010-09-23 Alios Biopharma, Inc. Protected nucleotide analogs
MX2011009728A (es) 2009-03-20 2011-10-14 Alios Biopharma Inc Analogos nucleotido y nucleosido sustituidos.
EA025341B1 (ru) 2010-09-22 2016-12-30 Алиос Биофарма, Инк. Замещенные аналоги нуклеотидов
AU2011305652B2 (en) 2010-09-22 2016-10-20 Janssen Biopharma, Inc. Azido nucleosides and nucleotide analogs
WO2012040126A1 (en) 2010-09-22 2012-03-29 Alios Biopharma, Inc. Substituted nucleotide analogs
EP2655392B1 (en) 2010-12-22 2018-04-18 Alios Biopharma, Inc. Cyclic nucleotide analogs
EA024297B1 (ru) 2011-12-20 2016-09-30 Рибосайенс Ллк 2',4'-дифтор-2'-метилзамещенные нуклеозидные производные в качестве ингибиторов репликации рнк вируса гепатита с
US8980865B2 (en) 2011-12-22 2015-03-17 Alios Biopharma, Inc. Substituted nucleotide analogs
SG10201610936RA (en) 2011-12-22 2017-02-27 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
CN104203253A (zh) 2012-03-21 2014-12-10 艾丽奥斯生物制药有限公司 取代的核苷、核苷酸及其类似物
EP2828278A4 (en) 2012-03-21 2015-12-09 Alios Biopharma Inc PROCESSES FOR PREPARING SUBSTITUTED NUCLEOTIDE ANALOGS
WO2013142159A1 (en) 2012-03-21 2013-09-26 Alios Biopharma, Inc. Pharmaceutical combinations comprising a thionucleotide analog
US8916538B2 (en) 2012-03-21 2014-12-23 Vertex Pharmaceuticals Incorporated Solid forms of a thiophosphoramidate nucleotide prodrug
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
HK1203356A1 (en) 2012-03-22 2015-10-30 艾丽奥斯生物制药有限公司 Pharmaceutical combinations comprising a thionucleotide analog
US9211300B2 (en) 2012-12-19 2015-12-15 Idenix Pharmaceuticals Llc 4′-fluoro nucleosides for the treatment of HCV
WO2014100498A1 (en) 2012-12-21 2014-06-26 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
CN110684067A (zh) 2012-12-21 2020-01-14 艾丽奥斯生物制药有限公司 取代的核苷和核苷酸
WO2014134251A1 (en) 2013-02-28 2014-09-04 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions
WO2014164533A1 (en) 2013-03-11 2014-10-09 Vertex Pharmaceuticals Incorporated Methods of stereoselective synthesis of substituted nucleoside analogs
WO2014165704A1 (en) 2013-04-05 2014-10-09 Vertex Pharmaceuticals, Inc. Hepatitis c viral infection treatment using a combination of compounds
EP3424938B1 (en) 2013-06-26 2020-07-22 Janssen BioPharma, Inc. 4'-azidoalkyl-substituted nucleosides, nucleotides and analogs thereof
US9815864B2 (en) 2013-06-26 2017-11-14 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
EP3043803B1 (en) * 2013-09-11 2022-04-27 Emory University Nucleotide and nucleoside compositions and their uses
AU2014331863C1 (en) 2013-10-11 2019-05-16 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
EA201692473A1 (ru) 2014-06-24 2017-03-31 Элиос Биофарма, Инк. Способы получения замещенных нуклеотидных аналогов
CN117379452A (zh) 2014-06-24 2024-01-12 艾丽奥斯生物制药有限公司 取代的核苷、核苷酸和其类似物
AU2015280234B2 (en) 2014-06-24 2021-04-01 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
CA2955604A1 (en) 2014-07-22 2016-01-28 Alios Biopharma, Inc. Methods for treating paramyxoviruses
EP3177299A4 (en) 2014-08-05 2018-04-04 Alios Biopharma, Inc. Combination therapy for treating a paramyxovirus
US9908914B2 (en) 2014-10-28 2018-03-06 Alios Biopharma, Inc. Methods of preparing substituted nucleoside analogs
MA41213A (fr) 2014-12-19 2017-10-24 Alios Biopharma Inc Nucléosides substitués, nucléotides et analogues de ceux-ci
MA41441A (fr) 2014-12-19 2017-12-12 Alios Biopharma Inc Nucléosides substitués, nucléotides et analogues de ceux-ci
MA45925A (fr) 2016-08-12 2019-06-19 Janssen Biopharma Inc Nucléosides et nucléotides substitués et leurs analogues
US20180117042A1 (en) 2016-10-27 2018-05-03 Alios Biopharma, Inc. Methods for treating respiratory syncytial virus infection
US11149049B2 (en) 2017-09-18 2021-10-19 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof

Also Published As

Publication number Publication date
JP2017519780A (ja) 2017-07-20
CA2952959C (en) 2023-03-07
MX2016017381A (es) 2017-08-14
EP3160475A4 (en) 2018-02-21
IL249627A0 (en) 2017-02-28
US20210106604A1 (en) 2021-04-15
US20170143751A1 (en) 2017-05-25
AU2015280234A1 (en) 2017-01-12
US10052342B2 (en) 2018-08-21
TW201613613A (en) 2016-04-16
JP6669675B2 (ja) 2020-03-18
US20150366887A1 (en) 2015-12-24
CN106604734B (zh) 2021-08-13
TN2016000566A1 (en) 2018-04-04
EP3160475B1 (en) 2024-01-03
EA201692537A1 (ru) 2017-05-31
AU2015280234B2 (en) 2021-04-01
US9603863B2 (en) 2017-03-28
PH12016502563A1 (en) 2017-04-17
US10780105B2 (en) 2020-09-22
EP3160475A1 (en) 2017-05-03
US11590155B2 (en) 2023-02-28
CN106604734A (zh) 2017-04-26
US20190054108A1 (en) 2019-02-21
SG11201610597QA (en) 2017-01-27
NZ727582A (en) 2018-06-29
EP3160475C0 (en) 2024-01-03
CA2952959A1 (en) 2015-12-30
WO2015200205A1 (en) 2015-12-30
AP2016009653A0 (en) 2016-12-31

Similar Documents

Publication Publication Date Title
PH12016502563A1 (en) Substituted nucleosides, nucleotides and analogs thereof
PH12016502564A1 (en) Substituted nucleosides, nucleosides and analogs thereof
MX2017008183A (es) Nucleosidos sustituidos, nucleotidos y analogos de estos.
MX2017008184A (es) Nucleosidos sustituidos, nucleotidos y analogos de estos.
PH12016500660A1 (en) Substituted nucleosides, nucleotides and analogs thereof
PH12015501423A1 (en) Substituted nucleosides, nucleotides and analogs thereof
PH12020551055A1 (en) Methods for treating filoviridae virus infections
WO2018031818A3 (en) Substituted nucleosides, nucleotides and analogs thereof
PH12015502799A1 (en) Substituted nucleosides, nucleotides and analogs thereof
PH12016502555A1 (en) Methods of preparing substituted nucleotide analogs
HK1243714A1 (zh) 制备取代的核苷类似物的方法
HK1216535A1 (zh) 取代的核苷、核苷酸及其類似物
HK1224229A1 (zh) 取代的核苷，核苷酸及其类似物
LT3265102T (lt) Beta-d-2'-deoksi-2'alfa-fluor-2'-beta-c-pakeistieji-2-modifikuoti-n6- pakeistieji purino nukleotidai, skirti hcv gydymui